Colorectal Cancer Metastatic Clinical Trial
Official title:
Evaluation of Prognostic and Predictive Value of PETSCAn in ColoRectal Cancer (CRC)
Study hypothesis : early decrease in fdg-pet measured SUV max after 1 cycle of chemotherapy
can accurately predict response of chemotherapy as assessed by conventional radiology after
3 cycles of chemotherapy.
FDG-PET imaging will be done at J0 and J14 of a new line of chemotherapy treatment in
metastatic colorectal cancer.
SUV max will be recorded and delta SUVmax will be compared to the results of conventional
radiological evaluation after 3 courses of chemotherapy. Results will also be compared to
the time to disease progression.
statistical hypothesis : Sample size calculation for FDG-PET in metastatic patients.
In the paper of Cascini et al. [1], they have 18 patients with a TRG response (TRG = Tumor
Regression Grade) and 15 patients with no response.
SUV mean was measured at baseline and at day 12 in all 33 patients. All 33 patients showed a
reduction in SUV-mean from baseline to day 12. The median reduction in SUV-mean was 63%
(mean 66%) in responding tumors and 22% (mean 22%) for non responding tumors. Using a cutoff
level of 52% a perfect accuracy could be obtained, i.e. all responding tumors had a SUV-mean
reduction higher than 52% and all non responding tumors had a SUV-mean reduction lower than
52%.
(Standard deviation of the SUV-mean reduction was 25.) All 33 patients showed also a
reduction in SUV-max from baseline to day 12. The median reduction in SUV-max was 62% in
responding tumors and 28% in non responding tumors. (No information about mean or standard
deviation of SUV-max available in [1].) Based on the data of SUV-mean we can do a power
calculation based on the Wilcoxon test: In order to demonstrate an absolute difference in
the mean of ΔSUV-mean of 44% between responding and non responding patients, with an
estimated standard deviation of 25, using 35 patients (50% response, 50% no response), at a
significance level of 5%, we obtain a power of 0.98.
For SUV-max, if we assume that the difference in the means is similar to the difference in
the medians, i.e. 34% and the standard deviation is similar to the one of SUV-mean, i.e. 25,
we obtain a power of 0.93 If we, to be safe, are a little bit less optimistic and estimate
that the difference in the mean of ΔSUV-max between responding and non responding tumors
would be a little lower than in [1]: 35%, and the standard deviation a little bit higher:
30, then we need 40 patients at a power of 0.90
Référence 1 : Cascini GL, Avallone A, Delrio P, Guida C, Tatangelo F, Marone P et al.:
F-18-FDG PET is an early predictor of pathologic tumor response to preoperative
radiochemotherapy in locally advanced rectal cancer. Journal of Nuclear Medicine 2006, 47:
1241-1248.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03941080 -
Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
|
||
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Completed |
NCT03647839 -
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT05057052 -
Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis
|
Phase 2 | |
Terminated |
NCT02316496 -
Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
|
Phase 2 | |
Completed |
NCT03251612 -
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02380443 -
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT02149784 -
Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients
|
Phase 3 | |
Recruiting |
NCT01959061 -
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
|
Phase 4 | |
Terminated |
NCT01668680 -
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
|
Phase 2 | |
Recruiting |
NCT05068531 -
Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
|
||
Not yet recruiting |
NCT04525807 -
Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
|
||
Completed |
NCT04482608 -
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
|
||
Recruiting |
NCT03193710 -
The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved
|
N/A | |
Recruiting |
NCT04854213 -
PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03142516 -
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
|
Phase 2 | |
Completed |
NCT03144804 -
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01910610 -
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
|
Phase 3 | |
Recruiting |
NCT05759728 -
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
|
Phase 1/Phase 2 |